Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company will hold a scientific symposium during ESICM Lives 2022, the annual congress of the European Society of Intensive Care Medicine. Additional data on inhaled sedation wil…
Non-regulatory
Sedana Medical AB (publ) plans to present its interim report for the third quarter 2022 in an audiocast on October 25 at 13.30 CET.
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has received Medical Device Regulation (MDR) certification, which secures EU market access for Sedaconda® ACD under the new MDR regulation, well ahead of the deadline in…
Regulatory
Committed to change the standard of care, with commercial progress and a strong balance sheet.
Non-regulatory
Sedana Medical AB (publ) plans to present its interim report for the second quarter 2022 in an audiocast on July 21 at 13.30 CET.
Regulatory
Today, the annual general meeting of Sedana Medical AB (publ) (SEDANA: FN Stockholm) was held. In order to counteract the spreading of the corona virus, the general meeting was held only through advance voting (so-called postal voting) in accordance…
Regulatory
First patient enrolled in US clinical program
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the first patient has been enrolled in the company’s US clinical studies. The two identical Phase III studies, INSPiRE-ICU 1 and 2, aim to confirm the efficacy and safety of inhaled…
Non-regulatory
Sedana Medical AB (publ) plans to present its interim report for the first quarter 2022 in an audiocast on April 28 at 13.30 CET.
Regulatory
The correction refers to incorrect reference to the Market Abuse Regulation, which was removed in this press release.
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) published its Annual Report 2021.
Regulatory
The shareholders in Sedana Medical AB (publ), reg. no. 556670-2519, are hereby given notice to attend the annual general meeting to be held Wednesday, 11 May 2022. In order to counteract the spreading of the corona virus, the board of directors of th…
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that a post hoc analysis on the Sedaconda study will be presented as a poster at the world’s largest conference for intensive care and emergency medicine, ISICEM, in Brussels on March 22…
Regulatory
Sales at an all-time-high provide a strong platform for launch
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the first bottles of Sedaconda (isoflurane) have been delivered to customers. The first sales were made in the company’s largest market Germany.
Non-regulatory
Sedana Medical AB (publ) plans to present its fourth quarter and Year-End Report for 2021 in an audiocast on February 17 at 13.30 CET.
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the National Institute for Health and Care Excellence (NICE) has issued positive guidance recommending Sedaconda ACD as a cost-saving option for delivering inhaled sedation in inten…
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces the appointment of Johan Spetz as the company’s new Chief Financial Officer (CFO). Johan Spetz will take office no later than April 4, 2022, succeeding Susanne Andersson who will leave h…
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to initiate phase III pivotal clinical trials with its Sedaconda pro…
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has submitted an application for market approval for Sedaconda (isoflurane) for inhaled sedation in intensive care in Italy.